Latest Cetrorelix Stories

All amounts are in U.S. dollars (unless otherwise noted) QUEBEC CITY, May 7, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"), a late stage drug development company specializing in oncology and endocrinology, today reported financial and operating results as at and for the first quarter ended March 31, 2013. Key Drug Developments AEZS-108 (Doxorubicin Peptide Conjugate) -- First patient treated for Phase 2 trial in...

All amounts are in US dollars (unless otherwise mentioned) QUÉBEC CITY, April 17, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that its German subsidiary has entered into binding agreements with various partners and licensees with respect to the manufacturing rights and obligations for its Cetrotide(®) product. The principal effect of such agreements is to transfer manufacturing rights and to grant a manufacturing license...

All amounts are in U.S. dollars (unless otherwise noted) QUEBEC CITY, May 9, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"), today reported financial and operating results as at and for the first quarter ended March 31, 2012. Highlights AEZS-108 (LHRH-Targeted Cytotoxic Conjugate) -- Agreement signed with Ventana Medical Systems, Inc., a member of the Roche Group, to develop a companion diagnostic for the...

All amounts are in U.S. dollars (unless otherwise noted) QUEBEC CITY, March 27, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"), a late-stage drug development company specializing in oncology and endocrine therapy, today reported financial and operating results as at and for the fourth quarter and the year ended December 31, 2011. 2011 Highlights Perifosine (Oral Akt Inhibitor) -- Agreement signed with Yakult Honsha Co.,...

All amounts are in U.S. dollars (except for share data). QUEBEC CITY, Nov. 10, 2011 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"), a late-stage drug development company specialized in oncology and endocrine therapy, today reported financial and operating results for the quarter ended September 30, 2011. Third Quarter 2011 Highlights Perifosine -- July 12, 2011: the Company announced that the European Patent...

All amounts are in U.S. dollars (unless otherwise noted) QUEBEC CITY, March 22 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"), a late-stage drug development company specialized in oncology and endocrine therapy, today reported financial and operating results as at and for the fourth quarter and the full year ended December 31, 2010. 2010 Highlights Perifosine (oral Akt inhibitor) -- February 3, 2010: Special...

All amounts are in U.S. dollars QUEBEC CITY, Feb. 28 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that it had received a net sales milestone of $2.5 million from Cowen Healthcare Royalty Partners, L.P. ("Cowen Royalty"). This milestone was payable pursuant to the previously announced sale to Cowen Royalty of Aeterna Zentaris' rights to...

All amounts are in U.S. dollars QUEBEC CITY, May 13 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) ("the Company"), a late-stage drug development company specialized in oncology and endocrinology, today reported financial and operating results as at and for the three months ended March 31, 2010. First Quarter 2010 Highlights - January 25, 2010: Updated results of a Phase 2 study related to the use of perifosine in the treatment of advanced metastatic...

QUEBEC CITY, Dec. 18 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on oncology and endocrine therapy, today announced the termination of its agreement with sanofi-aventis U.S. (NYSE: SNY) dated March 5, 2009 for the development, commercialization and licensing of cetrorelix in benign prostatic hyperplasia (BPH) for the U.S. market, following the Company's announcement last week of the results for its...

QUEBEC CITY, Sept. 30 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported that the 043 Thorough QT (TQT) trial, which is part of the cetrorelix pamoate clinical development program in benign prostatic hyperplasia (BPH), met its primary endpoint. Results showed that cetrorelix did not increase heart rate-corrected QT interval (QTc) at either time of observed...